Nanolymf Ltd.
This article was originally published in Start Up
Executive Summary
Israeli start-up Nanolymf . believes its technology could be used to create oral versions of some of the biggest intravenous and injectable drugs on today's market, including lipophilic drugs that are not readily bioavailable because of biochemical barriers that block their absorption. Nanolymf's nanoencapsulation technology allows the drug to bypass metabolic filters in the intestine and liver, resulting in increased bioavailability following oral administration.
You may also be interested in...
Start-Up Previews (04/2008)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Nanotechnology, a Balm for the Challenges of Drug Delivery," features profiles of BIND Biosciences, Liquidia Technologies, Nanolymf, Tempo Pharmaceuticals, and TransGenex Nanobiotech. Plus these Start-Ups Across Health Care: Breathe Technologies, Crospon, and InterMed Discovery.
TransGenex Nanobiotech Inc.
TransGenex Nanobiotech is taking a multi-pronged approach to building a nanotechnology company. In the short term, the company is generating revenue from sales of its custom nanoparticles and its Nanogene reagents that can be used to deliver genes to cells. It is also using its technology to develop diagnostic platforms, especially for lung and ovarian cancer. Finally, TransGenex plans to develop its own novel drug candidates. It's focusing first on products with anti-inflammatory properties, which could find application in asthma as well as several cancers.
Tempo Pharmaceuticals Inc.
Tempo Pharmaceuticals produces nano-sized therapeutics designed to deliver a one-two punch: the targeted and sequential release of two drugs at a specific location in the body. Though the technology offers an improved way to deliver drugs, especially highly toxic chemotherapeutics to treat cancer, the company shies away from the drug delivery label. The company says its technology isn't just about getting drug into a tumor; it's about getting the right drug to the right location at the right time to address the microenvironment of the disease.